CASTLE BIOSCIENCES, INC. (CSTL) Current Ratio
- Current ratio · latest quarter: Value 6.04×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.04× | Current assets / current liabilities. $341.10M ÷ $56.51M ≈ 6.04× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 341.10M USD | Assets, Current |
| Current obligations | 56.51M USD | Liabilities, Current |
| Cash and equivalents | 62.12M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 204.69M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 48.34M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 10.58M USD | Inventory, Net |
| Payables | 9.67M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 2.92M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $341.10M | $56.51M | $62.12M | $204.69M | $48.34M | $10.58M | $9.67M | $2.92M | 6.04× |
| 2026-03-31 | $328.90M | $48.76M | $63.76M | $197.92M | $42.26M | $10.46M | $15.04M | $1.67M | 6.75× |
| 2025-12-31 | $361.10M | $68.68M | $116.73M | $182.78M | $43.38M | $10.25M | $18.71M | $417.00K | 5.26× |
| 2025-09-30 | $357.57M | $55.31M | $85.56M | $201.99M | $49.48M | $8.65M | $12.21M | $0.00 | 6.47× |
| 2025-06-30 | $348.67M | $50.89M | $82.23M | $193.70M | $52.31M | $8.37M | $13.18M | $1.94M | 6.85× |
| 2025-03-31 | $349.39M | $37.27M | $89.69M | $185.46M | $56.35M | $6.85M | $8.50M | $1.11M | 9.37× |
| 2024-12-31 | $360.15M | $49.39M | $119.71M | $173.42M | $51.22M | $8.13M | $6.90M | $278.00K | 7.29× |
| 2024-09-30 | $344.77M | $44.30M | $94.96M | $184.83M | $50.26M | $6.57M | $6.81M | $0.00 | 7.78× |
| 2024-06-30 | $320.40M | $39.45M | $85.57M | $174.12M | $45.99M | $8.01M | $9.54M | $0.00 | 8.12× |
| 2024-03-31 | $295.78M | $31.96M | $82.95M | $156.26M | $42.70M | $7.64M | $9.32M | $0.00 | 9.25× |
| 2023-12-31 | $295.63M | $47.67M | $98.84M | $144.26M | $38.30M | $7.94M | $10.27M | $0.00 | 6.20× |
| 2023-09-30 | $279.62M | $36.32M | $91.22M | $138.53M | $37.00M | $5.77M | $6.93M | (m) | 7.70× |
| 2023-06-30 | $269.05M | $33.72M | $95.87M | $129.63M | $31.31M | $6.12M | $7.13M | (m) | 7.98× |
| 2023-03-31 | $271.10M | $30.14M | $114.82M | $117.23M | $27.73M | $4.52M | $9.96M | (m) | 8.99× |
| 2022-12-31 | $292.29M | $36.13M | $122.95M | $135.68M | $23.48M | $3.98M | $4.73M | (m) | 8.09× |
| 2022-09-30 | $299.41M | $31.94M | $134.18M | $131.80M | $22.84M | $3.80M | $5.77M | (m) | 9.37× |
| 2022-06-30 | $304.91M | $27.52M | $273.17M | (m) | $22.61M | $3.37M | $3.28M | (m) | 11.08× |
| 2022-03-31 | $336.44M | $39.52M | $309.02M | (m) | $19.91M | $2.35M | $3.31M | (m) | 8.51× |
| 2021-12-31 | $353.74M | $24.89M | $329.63M | $0.00 | $17.28M | $2.02M | $2.55M | (m) | 14.21× |
| 2021-09-30 | $389.58M | $20.99M | $363.18M | (m) | $18.53M | $2.38M | $2.77M | (m) | 18.56× |
| 2021-06-30 | $391.70M | $18.65M | $368.34M | (m) | $17.82M | $2.12M | $1.37M | (m) | 21.00× |
| 2021-03-31 | $426.67M | $17.58M | $406.98M | (m) | $14.29M | $2.31M | $2.17M | (m) | 24.27× |
| 2020-12-31 | $429.59M | $20.88M | $409.85M | (m) | $12.76M | $2.22M | $2.10M | (m) | 20.58× |
| 2020-09-30 | $201.06M | $30.24M | $183.05M | (m) | $12.62M | $1.68M | $2.10M | $10.00M | 6.65× |
| 2020-06-30 | $195.67M | $28.24M | $179.76M | (m) | $12.53M | $1.67M | $2.50M | $10.00M | 6.93× |
| 2020-03-31 | $116.55M | $15.26M | $98.65M | (m) | $14.60M | $1.22M | $1.93M | $8.33M | 7.64× |
| 2019-12-31 | $116.68M | $15.29M | $98.84M | (m) | $14.65M | $1.24M | $1.86M | $5.83M | 7.63× |
| 2019-09-30 | $109.86M | $9.24M | $94.47M | (m) | $12.37M | $821.66K | $1.25M | $3.33M | 11.89× |
| 2019-06-30 | $28.52M | $11.75M | $17.47M | (m) | $9.73M | $550.89K | $2.08M | $833.33K | 2.43× |
| 2018-12-31 | $18.13M | $6.74M | $4.48M | (m) | $12.09M | $882.00K | $1.45M | $0.00 | 2.69× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |